Up to 15-year Clinical Follow-Up of a Pilot Phase III Immunotherapy Study in Stage II Breast Cancer Patients Using Oxidized Mannan–MUC1

Abstract

The preliminary evidence indicates that M-FP is beneficial in the overall survival of early-stage breast cancer patients. This long-term clinical follow-up of patients strongly supports the necessity for a large Phase III study of direct M-FP injection in early-stage breast cancer patients, to evaluate immunotherapy as an adjuvant treatment for breast cancer.